> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Roivant Scraps Sarcoidosis Drug After Failed Trial
- URL: https://www.fdaweb.com/roivant-scraps-sarcoidosis-drug-after-failed-trial/
- Published: 2024-12-03T12:00:00.000Z
- Updated: 2026-09-14T14:48:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158287

Roivant says its Kinevant Sciences unit is discontinuing its development of namilumab for treating sarcoidosis after a Phase 2 study failed to show treatment benefit. The Phase 2 RESOLVE-Lung study (NCT05314517) “failed to meet the primary endpoint of proportion of subjects with a rescue event during the double-blind period,” Roivant says. “Secondary efficacy endpoints, including change in percent predicted forced vital capacity, corticosteroid tapering success, and change in the patient-reported King’s Sarcoidosis Questionnaire failed to show a treatment benefit consistent with the primary endpoint,” it adds.

Regarding safety, the company says namilumab’s profile in RESOLVE-Lung remains similar to previous studies. Results of the study will be published at a later date to inform future sarcoidosis research, it says.

Namilumab is described as a granulocyte macrophage colony stimulating factor (GM-CSF). The company says GM-CSF-mediated pro-inflammatory signaling is thought to play a key role in recruitment of macrophages and monocytes to the lung and to trigger a granulomatous response.